Acceleron Pharma Cmn (XLRN) 34.75 $XLRN
Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases
BusinessWire - Fri Jul 08, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced ACE-083 Phase 1 clinical trial results in healthy volunteers at the 14th International Congress on Neuromuscular Diseases in Toronto, Canada. ACE-083 is designed to selectively increase muscle mass and strength in the muscles in which the drug is administered.
XLRN: 34.75 (+0.84)
Acceleron Announces Presentation of ACE-083 Phase 1 Healthy Volunteer Data at the 14th International Congress on Neuromuscular Disease
BusinessWire - Wed Jun 29, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that results from the Phase 1 clinical trial with the therapeutic candidate ACE-083, will be presented at the 14th International Congress on Neuromuscular Disease (ICNMD 2016). The meeting will be held in Toronto, Canada from July 5-9, 2016.
XLRN: 34.75 (+0.84)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 34.75 (+0.84), CELGZ: 1.43 (+0.08)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.75 (+0.84), CELGZ: 1.43 (+0.08), CELG: 105.03 (+0.62)
Acceleron Pharma to Host Conference Call and Webcast to Review Updated Luspatercept Results Presented at the 21st Congress of the European Hematology Association
BusinessWire - Tue Jun 07, 3:00PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a conference call and live webcast on Friday, June 10, 2016, at 8:00 AM EDT (2:00 PM CEST) to review preliminary results from the luspatercept ongoing Phase 2 clinical trials in myelodysplastic syndromes and beta-thalassemia being presented at the 21st Congress of the European Hematology Association (EHA).
XLRN: 34.75 (+0.84)
Acceleron Pharma to Participate in Two Healthcare Investor Conferences in June
BusinessWire - Wed Jun 01, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that senior management will participate in two upcoming healthcare investor conferences in June.
XLRN: 34.75 (+0.84)
Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association
BusinessWire - Thu May 19, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that data from four abstracts with the therapeutic candidate luspatercept, were accepted for presentation at the 21st Congress of the European Hematology Association (EHA). The meeting will be held in Copenhagen, Denmark from June 9-12, 2016.
XLRN: 34.75 (+0.84)
Zacks.com featured expert Kevin Matras highlights: Acceleron Pharma, Clear Channel Outdoor, Gulfport Energy and Earthlink Holdings
Zacks Equity Research - Zacks Investment Research - Wed May 11, 8:30AM CDT
Zacks.com featured expert Kevin Matras highlights: Acceleron Pharma, Clear Channel Outdoor, Gulfport Energy and Earthlink Holdings
CCO: 6.59 (+0.27), ELNK: 6.55 (+0.20), GPOR: 30.80 (+0.84), XLRN: 34.75 (+0.84)
Acceleron tops Street 1Q forecasts
Automated Insights - Thu May 05, 6:24AM CDT
CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Thursday reported first-quarter net income of $5.1 million, after reporting a loss in the same period a year earlier.
XLRN: 34.75 (+0.84)
Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results
BusinessWire - Thu May 05, 6:00AM CDT
--- Raised $140.3 million in net proceeds to advance wholly owned programs -
XLRN: 34.75 (+0.84), CELGZ: 1.43 (+0.08)
New Strong Sell Stocks for May 2nd
Zacks Equity Research - Zacks Investment Research - Mon May 02, 8:29AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
CCLP: 7.96 (+0.21), ACW: 1.23 (+0.01), GNC: 25.53 (+0.81), EMG: 3.37 (+0.02), XLRN: 34.75 (+0.84)
Acceleron Pharma to Host First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:05PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a conference call and live webcast on Thursday, May 5, 2016 at 8:00 a.m. EDT to report its first quarter 2016 financial results and provide a corporate update.
XLRN: 34.75 (+0.84)
Acceleron Pharma to Participate in Two Healthcare Investor Conferences in May
BusinessWire - Tue Apr 26, 3:30PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that senior management will participate in two upcoming healthcare investor conferences in May.
XLRN: 34.75 (+0.84)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 85.70 (+2.17), IMGN: 3.20 (+0.08), ARQL: 1.74 (+0.08), LLY: 79.66 (+0.34), GSK: 43.38 (+0.04), ONTY: 1.21 (+0.02), MDVN: 62.10 (-0.64), MRK: 59.35 (+0.57), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), GALE: 0.46 (-0.05), PBYI: 34.88 (+2.73), NVS: 82.13 (+0.33), KPTI: 7.11 (+0.01), XLRN: 34.75 (+0.84), EXEL: 8.15 (+0.01)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 21.28 (+0.86), BSPM: 4.58 (-0.42), ADRO: 12.66 (+0.22), ARWR: 5.73 (+0.17), ARQL: 1.74 (+0.08), AMGN: 161.10 (+4.51), CASI: 1.03 (-0.01), BMY: 75.28 (+1.20), CLBS: 0.57 (+0.03), AAAP: 30.72 (unch), CANF: 2.28 (+0.03), ABUS: 3.91 (-0.08), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), ABBV: 64.16 (+0.73), XLRN: 34.75 (+0.84), ARRY: 3.71 (+0.03)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.47 (unch), AMBX: (), CLDX: 4.64 (-0.01), ARQL: 1.74 (+0.08), CTIC: 0.35 (-0.01), CTMX: 10.71 (+0.51), ABBV: 64.16 (+0.73), XLRN: 34.75 (+0.84), ADXS: 8.61 (+0.04), AMGN: 161.10 (+4.51), BIND: 0.56 (+0.01), BMY: 75.28 (+1.20), BPTH: 1.79 (unch), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), CELGZ: 1.43 (+0.08)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.48 (+0.11), CVM: 0.47 (unch), CLDX: 4.64 (-0.01), IMGN: 3.20 (+0.08), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BIND: 0.56 (+0.01), GSK: 43.38 (+0.04), BMY: 75.28 (+1.20), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), ABBV: 64.16 (+0.73), XLRN: 34.75 (+0.84)
Hepatocellular Carcinoma Market Report - Pipeline Review H2 2015
M2 - Wed Feb 03, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/wxjg2n/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: Introduction Hepatocellular Carcinoma Overview Therapeutics Development Pipeline Products for Hepatocellular Carcinoma - Overview Pipeline Products for Hepatocellular Carcinoma - Comparative Analysis Hepatocellular Carcinoma - Therapeutics under Development by Companies Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes Hepatocellular Carcinoma - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Hepatocellular Carcinoma - Products under Development by Companies Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes Hepatocellular Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - AndroScience Corporation - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - Bioneer Corporation - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. - CCRP Therapeutics GmbH - Celgene Corporation - Celldex Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/wx...tocellular
BPMC: 21.28 (+0.86), CLDX: 4.64 (-0.01), ARQL: 1.74 (+0.08), AMGN: 161.10 (+4.51), CASI: 1.03 (-0.01), BMY: 75.28 (+1.20), CLBS: 0.57 (+0.03), CANF: 2.28 (+0.03), ABUS: 3.91 (-0.08), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), ABBV: 64.16 (+0.73), CELGZ: 1.43 (+0.08), XLRN: 34.75 (+0.84), ARRY: 3.71 (+0.03)
Sickle Cell Disease Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44gnx8/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Sickle Cell Disease Overview - Therapeutics Development - Pipeline Products for Sickle Cell Disease - Overview - Pipeline Products for Sickle Cell Disease - Comparative Analysis - Sickle Cell Disease - Therapeutics under Development by Companies - Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes - Sickle Cell Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Sickle Cell Disease - Products under Development by Companies - Sickle Cell Disease - Products under Investigation by Universities/Institutes - Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Complexa, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - La Jolla Pharmaceutical Company - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sancilio & Company, Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/44...ickle_cell
JNJ: 122.85 (+0.34), GBT: 17.62 (+0.56), ISIS: 57.56 (-0.28), GILD: 86.55 (+1.08), PFE: 36.12 (+0.35), SGMO: 6.18 (+0.08), BMY: 75.28 (+1.20), NVS: 82.13 (+0.33), XLRN: 34.75 (+0.84)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 85.70 (+2.17), IMGN: 3.20 (+0.08), ARQL: 1.74 (+0.08), LLY: 79.66 (+0.34), GSK: 43.38 (+0.04), ONTY: 1.21 (+0.02), MDVN: 62.10 (-0.64), MRK: 59.35 (+0.57), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), GALE: 0.46 (-0.05), PBYI: 34.88 (+2.73), NVS: 82.13 (+0.33), KPTI: 7.11 (+0.01), XLRN: 34.75 (+0.84), EXEL: 8.15 (+0.01)
Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases
BusinessWire - Fri Jul 08, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced ACE-083 Phase 1 clinical trial results in healthy volunteers at the 14th International Congress on Neuromuscular Diseases in Toronto, Canada. ACE-083 is designed to selectively increase muscle mass and strength in the muscles in which the drug is administered.
XLRN: 34.75 (+0.84)
Acceleron Announces Presentation of ACE-083 Phase 1 Healthy Volunteer Data at the 14th International Congress on Neuromuscular Disease
BusinessWire - Wed Jun 29, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that results from the Phase 1 clinical trial with the therapeutic candidate ACE-083, will be presented at the 14th International Congress on Neuromuscular Disease (ICNMD 2016). The meeting will be held in Toronto, Canada from July 5-9, 2016.
XLRN: 34.75 (+0.84)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 34.75 (+0.84), CELGZ: 1.43 (+0.08)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.75 (+0.84), CELGZ: 1.43 (+0.08), CELG: 105.03 (+0.62)
Acceleron Pharma to Host Conference Call and Webcast to Review Updated Luspatercept Results Presented at the 21st Congress of the European Hematology Association
BusinessWire - Tue Jun 07, 3:00PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a conference call and live webcast on Friday, June 10, 2016, at 8:00 AM EDT (2:00 PM CEST) to review preliminary results from the luspatercept ongoing Phase 2 clinical trials in myelodysplastic syndromes and beta-thalassemia being presented at the 21st Congress of the European Hematology Association (EHA).
XLRN: 34.75 (+0.84)
Acceleron Pharma to Participate in Two Healthcare Investor Conferences in June
BusinessWire - Wed Jun 01, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that senior management will participate in two upcoming healthcare investor conferences in June.
XLRN: 34.75 (+0.84)
Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association
BusinessWire - Thu May 19, 6:00AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that data from four abstracts with the therapeutic candidate luspatercept, were accepted for presentation at the 21st Congress of the European Hematology Association (EHA). The meeting will be held in Copenhagen, Denmark from June 9-12, 2016.
XLRN: 34.75 (+0.84)
Zacks.com featured expert Kevin Matras highlights: Acceleron Pharma, Clear Channel Outdoor, Gulfport Energy and Earthlink Holdings
Zacks Equity Research - Zacks Investment Research - Wed May 11, 8:30AM CDT
Zacks.com featured expert Kevin Matras highlights: Acceleron Pharma, Clear Channel Outdoor, Gulfport Energy and Earthlink Holdings
CCO: 6.59 (+0.27), ELNK: 6.55 (+0.20), GPOR: 30.80 (+0.84), XLRN: 34.75 (+0.84)
Acceleron tops Street 1Q forecasts
Automated Insights - Thu May 05, 6:24AM CDT
CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Thursday reported first-quarter net income of $5.1 million, after reporting a loss in the same period a year earlier.
XLRN: 34.75 (+0.84)
Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results
BusinessWire - Thu May 05, 6:00AM CDT
--- Raised $140.3 million in net proceeds to advance wholly owned programs -
XLRN: 34.75 (+0.84), CELGZ: 1.43 (+0.08)
New Strong Sell Stocks for May 2nd
Zacks Equity Research - Zacks Investment Research - Mon May 02, 8:29AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
CCLP: 7.96 (+0.21), ACW: 1.23 (+0.01), GNC: 25.53 (+0.81), EMG: 3.37 (+0.02), XLRN: 34.75 (+0.84)
Acceleron Pharma to Host First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:05PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a conference call and live webcast on Thursday, May 5, 2016 at 8:00 a.m. EDT to report its first quarter 2016 financial results and provide a corporate update.
XLRN: 34.75 (+0.84)
Acceleron Pharma to Participate in Two Healthcare Investor Conferences in May
BusinessWire - Tue Apr 26, 3:30PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that senior management will participate in two upcoming healthcare investor conferences in May.
XLRN: 34.75 (+0.84)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 85.70 (+2.17), IMGN: 3.20 (+0.08), ARQL: 1.74 (+0.08), LLY: 79.66 (+0.34), GSK: 43.38 (+0.04), ONTY: 1.21 (+0.02), MDVN: 62.10 (-0.64), MRK: 59.35 (+0.57), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), GALE: 0.46 (-0.05), PBYI: 34.88 (+2.73), NVS: 82.13 (+0.33), KPTI: 7.11 (+0.01), XLRN: 34.75 (+0.84), EXEL: 8.15 (+0.01)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 21.28 (+0.86), BSPM: 4.58 (-0.42), ADRO: 12.66 (+0.22), ARWR: 5.73 (+0.17), ARQL: 1.74 (+0.08), AMGN: 161.10 (+4.51), CASI: 1.03 (-0.01), BMY: 75.28 (+1.20), CLBS: 0.57 (+0.03), AAAP: 30.72 (unch), CANF: 2.28 (+0.03), ABUS: 3.91 (-0.08), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), ABBV: 64.16 (+0.73), XLRN: 34.75 (+0.84), ARRY: 3.71 (+0.03)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.47 (unch), AMBX: (), CLDX: 4.64 (-0.01), ARQL: 1.74 (+0.08), CTIC: 0.35 (-0.01), CTMX: 10.71 (+0.51), ABBV: 64.16 (+0.73), XLRN: 34.75 (+0.84), ADXS: 8.61 (+0.04), AMGN: 161.10 (+4.51), BIND: 0.56 (+0.01), BMY: 75.28 (+1.20), BPTH: 1.79 (unch), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), CELGZ: 1.43 (+0.08)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.48 (+0.11), CVM: 0.47 (unch), CLDX: 4.64 (-0.01), IMGN: 3.20 (+0.08), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BIND: 0.56 (+0.01), GSK: 43.38 (+0.04), BMY: 75.28 (+1.20), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), ABBV: 64.16 (+0.73), XLRN: 34.75 (+0.84)
Hepatocellular Carcinoma Market Report - Pipeline Review H2 2015
M2 - Wed Feb 03, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/wxjg2n/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: Introduction Hepatocellular Carcinoma Overview Therapeutics Development Pipeline Products for Hepatocellular Carcinoma - Overview Pipeline Products for Hepatocellular Carcinoma - Comparative Analysis Hepatocellular Carcinoma - Therapeutics under Development by Companies Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes Hepatocellular Carcinoma - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Hepatocellular Carcinoma - Products under Development by Companies Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes Hepatocellular Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - AndroScience Corporation - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - Bioneer Corporation - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. - CCRP Therapeutics GmbH - Celgene Corporation - Celldex Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/wx...tocellular
BPMC: 21.28 (+0.86), CLDX: 4.64 (-0.01), ARQL: 1.74 (+0.08), AMGN: 161.10 (+4.51), CASI: 1.03 (-0.01), BMY: 75.28 (+1.20), CLBS: 0.57 (+0.03), CANF: 2.28 (+0.03), ABUS: 3.91 (-0.08), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), ABBV: 64.16 (+0.73), CELGZ: 1.43 (+0.08), XLRN: 34.75 (+0.84), ARRY: 3.71 (+0.03)
Sickle Cell Disease Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44gnx8/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Sickle Cell Disease Overview - Therapeutics Development - Pipeline Products for Sickle Cell Disease - Overview - Pipeline Products for Sickle Cell Disease - Comparative Analysis - Sickle Cell Disease - Therapeutics under Development by Companies - Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes - Sickle Cell Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Sickle Cell Disease - Products under Development by Companies - Sickle Cell Disease - Products under Investigation by Universities/Institutes - Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Complexa, Inc. - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - La Jolla Pharmaceutical Company - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sancilio & Company, Inc. - Sangamo BioSciences, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/44...ickle_cell
JNJ: 122.85 (+0.34), GBT: 17.62 (+0.56), ISIS: 57.56 (-0.28), GILD: 86.55 (+1.08), PFE: 36.12 (+0.35), SGMO: 6.18 (+0.08), BMY: 75.28 (+1.20), NVS: 82.13 (+0.33), XLRN: 34.75 (+0.84)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 85.70 (+2.17), IMGN: 3.20 (+0.08), ARQL: 1.74 (+0.08), LLY: 79.66 (+0.34), GSK: 43.38 (+0.04), ONTY: 1.21 (+0.02), MDVN: 62.10 (-0.64), MRK: 59.35 (+0.57), AZN: 30.11 (unch), AVEO: 0.95 (+0.02), GALE: 0.46 (-0.05), PBYI: 34.88 (+2.73), NVS: 82.13 (+0.33), KPTI: 7.11 (+0.01), XLRN: 34.75 (+0.84), EXEL: 8.15 (+0.01)
